FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4237162476> ?p ?o ?g. }

• W4237162476 endingPage "e14634" @default.
• W4237162476 startingPage "e14634" @default.
• W4237162476 abstract "e14634 Background: Introducing amino acid sequence changes in highly expressed self-antigens for prostate cancer (PCa) patients (pts) might lead to avoidance of immune tolerance. We evaluated a DNA vaccine (INO-5150) including SynCon PSA and PSMA. Administration of INO-5150 to PCa pts along with plasmid encoded adjuvant IL-12 (INO-9012) via electroporation (EP) is postulated to break tolerance, resulting in antigen-specific immune responses which could lead to stabilization of disease progression. Methods: Phase I, open-label, multicenter study of PCa pts post-definitive therapy with a rising PSA ≥ 1.0 ng/ml after surgery, or ≥ 2.0 ng/ml above nadir after RT and PSADT > 3 months, testosterone > 150 ng/dL, no concomitant androgen deprivation therapy and no evidence of metastases within 12 months. We evaluated safety, tolerability and for efficacy signals. INO-5150 low (2 mg, arms A and C) or high (8.5 mg, arms B and D) dose with or without INO-9012 (1 mg) was administered IM followed by EP in total 4 dosing arms on Day 0 and at Wks 3, 12, and 24 in 60 planned pts (15/arm). Pts were followed for 72 Wks. Results: 62 pts, 16 each in arms A and D and 15 in B and C were enrolled. Median age: 69.5 yrs (range 55.4-87.7), Gleason score: 7 (5-10), time from initial diagnosis: 8.2 yrs (0.5-23.8) and ECOG PS: 0 (0-1). As of data cutoff of 23Jan17, 52 pts had EOT visit, 7 withdrawn from treatment and 6 (10%) reported disease progression, 3 biochemical and 3 radiographic. Median serum PSA at enrollment was 4.6 ng/mL (range 1.2, 113.7) and at EOT was 6.5 ng/mL (0.1, 73.6). Median PSADT at enrollment was 8.7 months (3.1, 218.1) and at EOT it was 3.1 months (-23.1, 100.0). Safety: no reports of Grade 4-5 SAEs. 6 Grade 3 SAEs in 5 pts: presyncope, cardiac disorder, fall, neoplasm, ALT and AST elevation. Grade 1-3 AEs reported in 51 (82%) pts: 12 (75%) in Arm A, 13 (87%) B, 13 (87%) C, and 13 (81%) in D. Common AEs were injection site pain (24/39%), swelling (14/23%), erythema (14/23%), all Grade 1-2. Conclusions: INO-5150 (+) and (-) INO-9012 was generally safe and well-tolerated at all 4 dose levels in this patient population. Preliminary data suggest PSA stabilization in some patients. Immune analyses are ongoing. (NCT02514213) Clinical trial information: NCT02514213." @default.
• W4237162476 created "2022-05-12" @default.
• W4237162476 creator A5000198604 @default.
• W4237162476 creator A5007663088 @default.
• W4237162476 creator A5011907185 @default.
• W4237162476 creator A5015377056 @default.
• W4237162476 creator A5015581478 @default.
• W4237162476 creator A5020296013 @default.
• W4237162476 creator A5032477670 @default.
• W4237162476 creator A5038021560 @default.
• W4237162476 creator A5041929329 @default.
• W4237162476 creator A5046669491 @default.
• W4237162476 creator A5055994794 @default.
• W4237162476 creator A5056587248 @default.
• W4237162476 creator A5057769917 @default.
• W4237162476 creator A5058352236 @default.
• W4237162476 creator A5071608389 @default.
• W4237162476 creator A5075347801 @default.
• W4237162476 creator A5088518998 @default.
• W4237162476 creator A5090355173 @default.
• W4237162476 date "2017-05-20" @default.
• W4237162476 modified "2023-10-05" @default.
• W4237162476 title "A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer." @default.
• W4237162476 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e14634" @default.
• W4237162476 hasPublicationYear "2017" @default.
• W4237162476 type Work @default.
• W4237162476 citedByCount "1" @default.
• W4237162476 countsByYear W42371624762018 @default.
• W4237162476 crossrefType "journal-article" @default.
• W4237162476 hasAuthorship W4237162476A5000198604 @default.
• W4237162476 hasAuthorship W4237162476A5007663088 @default.
• W4237162476 hasAuthorship W4237162476A5011907185 @default.
• W4237162476 hasAuthorship W4237162476A5015377056 @default.
• W4237162476 hasAuthorship W4237162476A5015581478 @default.
• W4237162476 hasAuthorship W4237162476A5020296013 @default.
• W4237162476 hasAuthorship W4237162476A5032477670 @default.
• W4237162476 hasAuthorship W4237162476A5038021560 @default.
• W4237162476 hasAuthorship W4237162476A5041929329 @default.
• W4237162476 hasAuthorship W4237162476A5046669491 @default.
• W4237162476 hasAuthorship W4237162476A5055994794 @default.
• W4237162476 hasAuthorship W4237162476A5056587248 @default.
• W4237162476 hasAuthorship W4237162476A5057769917 @default.
• W4237162476 hasAuthorship W4237162476A5058352236 @default.
• W4237162476 hasAuthorship W4237162476A5071608389 @default.
• W4237162476 hasAuthorship W4237162476A5075347801 @default.
• W4237162476 hasAuthorship W4237162476A5088518998 @default.
• W4237162476 hasAuthorship W4237162476A5090355173 @default.
• W4237162476 hasConcept C121608353 @default.
• W4237162476 hasConcept C126322002 @default.
• W4237162476 hasConcept C126894567 @default.
• W4237162476 hasConcept C141071460 @default.
• W4237162476 hasConcept C147483822 @default.
• W4237162476 hasConcept C197934379 @default.
• W4237162476 hasConcept C203014093 @default.
• W4237162476 hasConcept C2777701055 @default.
• W4237162476 hasConcept C2777863537 @default.
• W4237162476 hasConcept C2777899217 @default.
• W4237162476 hasConcept C2778375690 @default.
• W4237162476 hasConcept C2779384505 @default.
• W4237162476 hasConcept C2780192828 @default.
• W4237162476 hasConcept C2780868878 @default.
• W4237162476 hasConcept C2781406297 @default.
• W4237162476 hasConcept C31760486 @default.
• W4237162476 hasConcept C535046627 @default.
• W4237162476 hasConcept C71924100 @default.
• W4237162476 hasConcept C90924648 @default.
• W4237162476 hasConceptScore W4237162476C121608353 @default.
• W4237162476 hasConceptScore W4237162476C126322002 @default.
• W4237162476 hasConceptScore W4237162476C126894567 @default.
• W4237162476 hasConceptScore W4237162476C141071460 @default.
• W4237162476 hasConceptScore W4237162476C147483822 @default.
• W4237162476 hasConceptScore W4237162476C197934379 @default.
• W4237162476 hasConceptScore W4237162476C203014093 @default.
• W4237162476 hasConceptScore W4237162476C2777701055 @default.
• W4237162476 hasConceptScore W4237162476C2777863537 @default.
• W4237162476 hasConceptScore W4237162476C2777899217 @default.
• W4237162476 hasConceptScore W4237162476C2778375690 @default.
• W4237162476 hasConceptScore W4237162476C2779384505 @default.
• W4237162476 hasConceptScore W4237162476C2780192828 @default.
• W4237162476 hasConceptScore W4237162476C2780868878 @default.
• W4237162476 hasConceptScore W4237162476C2781406297 @default.
• W4237162476 hasConceptScore W4237162476C31760486 @default.
• W4237162476 hasConceptScore W4237162476C535046627 @default.
• W4237162476 hasConceptScore W4237162476C71924100 @default.
• W4237162476 hasConceptScore W4237162476C90924648 @default.
• W4237162476 hasIssue "15_suppl" @default.
• W4237162476 hasLocation W42371624761 @default.
• W4237162476 hasOpenAccess W4237162476 @default.
• W4237162476 hasPrimaryLocation W42371624761 @default.
• W4237162476 hasRelatedWork W12944646 @default.
• W4237162476 hasRelatedWork W15992128 @default.
• W4237162476 hasRelatedWork W16536396 @default.
• W4237162476 hasRelatedWork W18396566 @default.
• W4237162476 hasRelatedWork W19887974 @default.
• W4237162476 hasRelatedWork W24028266 @default.
• W4237162476 hasRelatedWork W2539398 @default.
• W4237162476 hasRelatedWork W3215447 @default.
• W4237162476 hasRelatedWork W437930 @default.

• next